Related references
Note: Only part of the references are listed.Zoledronic Acid Use in Cancer Patients More Than Just Supportive Care?
Robert Coleman et al.
CANCER (2011)
EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate Cancer
Nicolas Mottet et al.
EUROPEAN UROLOGY (2011)
The benefits of timely intervention with zoledronic acid in patients with metastatic prostate cancer to bones: a retrospective study of the US Veterans Affairs population
N. V. Velde et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2011)
Prognostic factors in metastatic prostate cancer
Orhan Yigitbasi et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2011)
Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study
H. Eidtmann et al.
ANNALS OF ONCOLOGY (2010)
Zoledronic Acid Improves Clinical Outcomes When Administered Before Onset of Bone Pain in Patients With Prostate Cancer
Fred Saad et al.
UROLOGY (2010)
Risk Assessment Among Prostate Cancer Patients Receiving Primary Androgen Deprivation Therapy
Matthew R. Cooperberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast Cancer
Michael Gnant et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole
Nigel J. Bundred et al.
CANCER (2008)
Exploring the anti-tumour activity of bisphosphonates in early breast cancer
M. C. Winter et al.
CANCER TREATMENT REVIEWS (2008)
Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel
M. Aapro et al.
ANNALS OF ONCOLOGY (2008)
Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients
Daniele Santini et al.
CLINICAL CANCER RESEARCH (2007)
Effects of skeletal morbidities on longitudinal patient-reported outcomes and survival in patients with metastatic prostate cancer
Venita DePuy et al.
SUPPORTIVE CARE IN CANCER (2007)
Zoledronic acid cooperates with a cyclooxygenase-2 inhibitor and gefitinib in inhibiting breast and prostate cancer
D Melisi et al.
ENDOCRINE-RELATED CANCER (2005)
Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients
B Vincenzi et al.
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH (2005)
Sequence- and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells
HL Neville-Webbe et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors
JE Brown et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer
F Saad et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2004)
Bone markers in the management of patients with skeletal metastases
LM Demers
CANCER (2003)
A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma
F Saad et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2002)
Metastatic bone disease: clinical features, pathophysiology and treatment strategies
RE Coleman
CANCER TREATMENT REVIEWS (2001)
Share Paper
